Vimian Group AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIMIAN.ST research report →
Companyvimian.com
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
- CEO
- Alireza Tajbakhsh
- IPO
- 2021
- Employees
- 1,200
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $15.41B
- P/E
- 39.08
- P/S
- 3.30
- P/B
- 1.98
- EV/EBITDA
- 14.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 55.65%
- Op Margin
- 18.50%
- Net Margin
- 8.49%
- ROE
- 5.25%
- ROIC
- 5.53%
Growth & Income
- Revenue
- $425.00M · 13.39%
- Net Income
- $31.30M · 69.19%
- EPS
- $0.06 · 63.49%
- Op Income
- $73.55M
- FCF YoY
- 106.38%
Performance & Tape
- 52W High
- $46.00
- 52W Low
- $24.18
- 50D MA
- $28.88
- 200D MA
- $29.24
- Beta
- 1.19
- Avg Volume
- 265.17K
Get TickerSpark's AI analysis on VIMIAN.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VIMIAN.ST Coverage
We haven't published any research on VIMIAN.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIMIAN.ST Report →